3731 related articles for article (PubMed ID: 3798106)
1. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
Slamon DJ; Clark GM; Wong SG; Levin WJ; Ullrich A; McGuire WL
Science; 1987 Jan; 235(4785):177-82. PubMed ID: 3798106
[TBL] [Abstract][Full Text] [Related]
2. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.
Andrulis IL; Bull SB; Blackstein ME; Sutherland D; Mak C; Sidlofsky S; Pritzker KP; Hartwick RW; Hanna W; Lickley L; Wilkinson R; Qizilbash A; Ambus U; Lipa M; Weizel H; Katz A; Baida M; Mariz S; Stoik G; Dacamara P; Strongitharm D; Geddie W; McCready D
J Clin Oncol; 1998 Apr; 16(4):1340-9. PubMed ID: 9552035
[TBL] [Abstract][Full Text] [Related]
3. The association of HER-2/neu amplification with breast cancer recurrence.
Carr JA; Havstad S; Zarbo RJ; Divine G; Mackowiak P; Velanovich V
Arch Surg; 2000 Dec; 135(12):1469-74. PubMed ID: 11115354
[TBL] [Abstract][Full Text] [Related]
4. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis.
Tiwari RK; Borgen PI; Wong GY; Cordon-Cardo C; Osborne MP
Anticancer Res; 1992; 12(2):419-25. PubMed ID: 1349794
[TBL] [Abstract][Full Text] [Related]
5. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
6. Cathepsin D assay in primary breast cancer and lymph nodes: relationship with c-myc, c-erb-B-2 and int-2 oncogene amplification and node invasiveness.
Brouillet JP; Theillet C; Maudelonde T; Defrenne A; Simony-Lafontaine J; Sertour J; Pujol H; Jeanteur P; Rochefort H
Eur J Cancer; 1990 Apr; 26(4):437-41. PubMed ID: 2141510
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status.
Torregrosa D; Bolufer P; Lluch A; López JA; Barragán E; Ruiz A; Guillem V; Munárriz B; García Conde J
Clin Chim Acta; 1997 Jun; 262(1-2):99-119. PubMed ID: 9204213
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in situ hybridization in breast cancer.
Depowski PL; Brien TP; Sheehan CE; Stylos S; Johnson RL; Ross JS
Am J Clin Pathol; 1999 Oct; 112(4):459-69. PubMed ID: 10510669
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.
Seshadri R; Firgaira FA; Horsfall DJ; McCaul K; Setlur V; Kitchen P
J Clin Oncol; 1993 Oct; 11(10):1936-42. PubMed ID: 8105035
[TBL] [Abstract][Full Text] [Related]
10. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
Press MF; Bernstein L; Thomas PA; Meisner LF; Zhou JY; Ma Y; Hung G; Robinson RA; Harris C; El-Naggar A; Slamon DJ; Phillips RN; Ross JS; Wolman SR; Flom KJ
J Clin Oncol; 1997 Aug; 15(8):2894-904. PubMed ID: 9256133
[TBL] [Abstract][Full Text] [Related]
11. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment.
Berns EM; Foekens JA; van Staveren IL; van Putten WL; de Koning HY; Portengen H; Klijn JG
Gene; 1995 Jun; 159(1):11-8. PubMed ID: 7607564
[TBL] [Abstract][Full Text] [Related]
12. HER-2/neu oncogene protein and prognosis in breast cancer.
Tandon AK; Clark GM; Chamness GC; Ullrich A; McGuire WL
J Clin Oncol; 1989 Aug; 7(8):1120-8. PubMed ID: 2569032
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
15. Amplification of HER-2(erbB-2/neu) oncogene as the most significant prognostic factor in a group of Russian breast cancer patients.
Imyanitov EN; Chernitsa OI; Serova OM; Nikoforova IF; Pluzhnikova GF; Knyazev PG
Neoplasma; 1993; 40(1):35-9. PubMed ID: 7688867
[TBL] [Abstract][Full Text] [Related]
16. C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer.
Schlotter CM; Vogt U; Bosse U; Mersch B; Wassmann K
Breast Cancer Res; 2003; 5(2):R30-6. PubMed ID: 12631396
[TBL] [Abstract][Full Text] [Related]
17. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
[TBL] [Abstract][Full Text] [Related]
18. HER-2/neu amplification predicts poor survival in node-positive breast cancer.
Borg A; Tandon AK; Sigurdsson H; Clark GM; Fernö M; Fuqua SA; Killander D; McGuire WL
Cancer Res; 1990 Jul; 50(14):4332-7. PubMed ID: 1973070
[TBL] [Abstract][Full Text] [Related]
19. Follow-up study of HER-2/neu amplification in primary breast cancer.
Clark GM; McGuire WL
Cancer Res; 1991 Feb; 51(3):944-8. PubMed ID: 1988136
[TBL] [Abstract][Full Text] [Related]
20. Amplification of the proto-oncogenes int-2, c-erb B-2 and c-myc in human breast cancer.
Machotka SV; Garrett CT; Schwartz AM; Callahan R
Clin Chim Acta; 1989 Oct; 184(3):207-17. PubMed ID: 2611995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
